Nine Case Studies Improve Your Single-Use Platform

Did you know that a production facility using single-use technologies can reduce capital costs by up to 40% compared to traditional stainless steel facilities?

Learn how industry leaders are utilizing the latest disposable technologies to increase productivity and lower costs while complying with regulatory guidelines at IBC's Single-Use Applications for Biopharmaceutical Manufacturing conference this June in Boston.

Over the last decade, this interactive conference has helped scientists, engineers, managers, directors and executives from across the globe design more efficient and economical single-use platforms.

Nine Case Studies Help You Overcome Complex Drug Product and Manufacturing Challenges:

Single-Use Systems in a Perfusion Cell Culture Process
Russell Wong, Ph.D., Principal Engineer, Bayer Health Care

Single-Use Cell-Expansion and Volume Reduction Technologies
Sally Hassan, Ph.D., Post-Doctoral Research Associate, University College London

Identifying and Solving a Cell Growth Inhibition Issue in Single-Use Shake Flasks
Olga Smiliotopoulos, M.S., Scientist, Culture Process Development, Pfizer Inc.

Production of Cell Culture-Based Influenza A Virus in Single-Use Bioreactors
J. David Gangemi, Ph.D., President and CSO, ViraCell Advanced Products, LLC

Single-Use Mixing systems in Large-scale Live-viral Vaccine Upstream Processes
Daniel C. Vellom, Ph.D., Senior Director, Sanofi Pasteur Biologics

Adopting a Fully Single-Use Process to Improve Speed to Clinic
Ross W. Acucena, Regulatory Consultant, EMD Millipore

A Closed Sterile System for Viral Vaccine Purification Using Single-Use Technologies
Julia Telychko, Associate Scientist, BioProcess R&D, Sanofi-Pasteur

Rational Selection and Capacity Improvement of Disposable Filters
Johannes Felix Buyel, M. Sc., Integrated Production Platforms, RWTH Aachen University

Single Use Systems - An End User's Perspective
Alex Tschumakow, Director, Manufacturing, Shire

To learn more, download our brochure.

Register with priority code XB14187BLOG to save 20% off of our standard rate:. If you have questions about the event, feel free to contact our group manager, Kate Devery (Kdevery@iirusa.com), or visit our webpage.

We look forward to seeing you June 9th-10th in Boston!

Cheers,
The Single-Use Team

Opt-in for updates

Follow us on Twitter
Single-Use LinkedIn

Share this article with your social network, just click below to share now!

Share |

BioProcess International Poster Preview: Linear Scalability of Virus Production in Integrity® iCELLis® Single-Use, Fixed-Bed Bioreactors From Bench Scale to Industrial Scale

Leading up to the BioProcess International Event, we'll be highlighting many of the posters you'll be able to find in the hall at the event taking place September 16-19, 2013 in Boston, MA. If you'd like to join us at the event, as a reader of this blog, when you register to join us and mention code BLOG13JP, you'll save 20% off the standard rate!


Poster: Linear Scalability of Virus Production in Integrity® iCELLis® Single-Use, Fixed-Bed Bioreactors From Bench Scale to Industrial Scale

Presenter: Stéphanie Dubois, ATMI LifeSciences

About: Viral vaccines are usually produced by anchorage-dependent cells in static multitray systems, roller bottles or bioreactors with microbeads. However, these technologies do not enable process intensification as they involve many manual operations. To enable process intensification, ATMI developed iCELLis®, a scalable range of disposable pre-packed fixed-bed bioreactors that operate in perfusion mode. The fixed-bed accommodates up to 500m² of growth surface area in only 25 liters reactor volume. It can be inoculated at a very low cell density which simplifies seed train. Here we present the scale-up of MDBK, Vero and HEK293 processes from iCELLis benchtop bioreactor to production units. Scaling-up with iCELLis systems is quick and similar to that of chromatography columns. As the bioreactor scale increases, the fixed-bed height remains constant while the diameter increases. Small scale processes were transferred to large scale iCELLis by keeping same culture parameters (pH, DO & Temp), identical ratios for cells/surface and media/cells, compaction of carriers, the linear speed through the fixed-bed and the perfusion rate. The study demonstrated that iCELLis bioreactors simplify viral production processes and that linear scale-up in iCELLis is easily developed from 0.53m² to 500m² in less than one year.

Share this article with your social network, just click below to share now!

Share |